Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
Pericarditis is rarely reported in inflammatory bowel disease. Besides its common causes, pericarditis could be related to ulcerative colitis flare or to 5-aminosalicylic acid (5-ASA) treatment. We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g. The patient recovered after treatment discontinuation and did not exhibit any recurrence of pericarditis when treatment with mesalazine was introduced. In conclusion, if pericarditis occurs in ulcerative colitis patients treated with 5-ASA compounds, the treatment should be considered as a possible cause, even after an increase of the dosage. In this case, discontinuation of the treatment and cautious switch to another 5-ASA compound should be tested.